Details

Autor(en) / Beteiligte

• Legro, Richard S
• Barnhart, Huiman X
• Schlaff, William D
• Carr, Bruce R
• Diamond, Michael P
• Carson, Sandra A
• Steinkampf, Michael P
• Coutifaris, Christos
• McGovern, Peter G
• Cataldo, Nicholas A
• Gosman, Gabriella G
• Nestler, John E
• Giudice, Linda C
• Leppert, Phyllis C
• Myers, Evan R

Titel

Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome

Ist Teil von

• The New England journal of medicine, 2007-02, Vol.356 (6), p.551-566

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2007

Quelle

MEDLINE

Beschreibungen/Notizen

• This multicenter, randomized trial compared the effects of clomiphene citrate plus placebo, metformin plus placebo, and combination therapy in infertile women with the polycystic ovary syndrome. The rate of live birth was significantly higher with clomiphene than with metformin; there was no significant difference between the rates with combination therapy and with clomiphene alone. Multiple birth was a complication associated with clomiphene but was infrequent. These data support the use of clomiphene over metformin for the treatment of infertility in women with the polycystic ovary syndrome. In infertile women with the polycystic ovary syndrome, the rate of live birth was significantly higher with clomiphene than with metformin. The polycystic ovary syndrome affects 7 to 8% of women 1 and may be the most common cause of female infertility. 2 Anovulation, 2 early pregnancy loss, 3 and later pregnancy complications 4 have all been implicated in the low fecundity of women with this disorder. Obesity is also common in such women, 5 and this condition alone appears to have an adverse effect on reproduction. 6 , 7 The cause of the polycystic ovary syndrome is poorly understood, and both the diagnosis and treatment of the disorder are controversial. 5 , 8 , 9 Women with this syndrome have hyperandrogenism, 10 morphologic changes in the ovary (polycystic), 10 inappropriate gonadotropin secretion (elevated . . .